preterm

Atosiban acetate (RW22164) is an inhibitor of the hormones oxytocin and vasopressin. It is used as an intravenous medication as a labour repressant (tocolytic) to halt premature labor. Atosiban acetate (RW22164) inhibits the oxytocin-mediated release of inositol trisphosphate from the myometrial cell membrane. As a result, there is reduced release of intracellular, stored calcium from the sarcoplasmic reticulum of myometrial cells, and reduced influx of Ca2+ from the extracellular space through voltage gated channels. In addition, Atosiban acetate (RW22164) suppresses oxytocin-mediated release of PGE and PGF from the decidua. In human pre-term labor, atosiban, at the recommended dosage, antagonizes uterine contractions and induces uterine quiescence. The onset of uterus relaxation following atosiban is rapid, uterine contractions being significantly reduced within 10 minutes to achieve stable uterine quiescence.

Atosiban (RW22164) is an inhibitor of the hormones oxytocin and vasopressin. It is used as an intravenous medication as a labour repressant (tocolytic) to halt premature labor. Atosiban inhibits the oxytocin-mediated release of inositol trisphosphate from the myometrial cell membrane. As a result, there is reduced release of intracellular, stored calcium from the sarcoplasmic reticulum of myometrial cells, and reduced influx of Ca2+ from the extracellular space through voltage gated channels. In addition, atosiban suppresses oxytocin-mediated release of PGE and PGF from the decidua. In human pre-term labor, atosiban, at the recommended dosage, antagonizes uterine contractions and induces uterine quiescence. The onset of uterus relaxation following atosiban is rapid, uterine contractions being significantly reduced within 10 minutes to achieve stable uterine quiescence.

PDC31 (THG113.31; ILGHXDYK) is a D-amino acid-based oligopeptide that acts as an allosteric and non-competitive inhibitor of the FP Prostaglandin Receptor, used primarily as a smooth muscle contractile agent. It effectively reduces the strength and duration of uterine contractions in vivo, offering potential for preterm labor and primary dysmenorrhea (PD) research. Additionally, PDC31 enhances the Ca2+-dependent large-conductance K+-channel in human myometrial cells [1] [2].

RYTVELA TFA (H-Arg-Tyr-Thr-Val-Glu-Leu-Ala-OH) is a non-competitive metabotropic interleukin-1 receptor inhibitor with anti-inflammatory activity that inhibits upregulation of inflammation and uterine activation, and may be used for the prevention of preterm labor and for fetal protection.

iE-DAP dihydrochloride is a Nod1 agonist that activates the NF-κB pathway through recognition by Nod1, leading to an inflammatory cytokine response. This compound is useful for studying maternal-fetal inflammation and preterm birth.